Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)

Author(s): Phil Skolnick, Anthony S. Basile

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 6 , Issue 2 , 2007

Become EABM
Become Reviewer


The majority of antidepressants in current use inhibit the uptake of serotonin and/or norepinephrine. Drugs inhibiting the uptake of serotonin, norepinephrine and dopamine (triple reuptake inhibitors) may offer therapeutic advantages compared to single and/or dual reuptake inhibitors. This review provides a rationale for developing this class of compound and describes the results of preclinical and clinical studies with a family of triple reuptake inhibitors.

Keywords: Antidepressant, dopamine, serotonin, norepinephrine, biogenic, amines, depression

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [141 - 149]
Pages: 9
DOI: 10.2174/187152707780363285
Price: $65

Article Metrics

PDF: 9